Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDMDNASDAQ:BSGMNASDAQ:DXRNASDAQ:POAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDMDBaird Medical Investment$5.18+0.6%$5.44$1.05▼$12.50$34.11M-0.74441,097 shs15,697 shsBSGMBioSig Technologies$1.94+8.4%$0.78$0.20▼$2.57$47.05M0.02247,166 shs1.01 million shsDXRDaxor$7.75+0.6%$7.80$6.55▼$10.00$37.49M-0.216,598 shs903 shsPOAIPredictive Oncology$1.11+3.7%$1.13$0.55▼$3.06$9.92M1.32.33 million shs73,314 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDMDBaird Medical Investment0.00%-4.25%+5.50%-12.20%+517,999,900.00%BSGMBioSig Technologies0.00%+41.61%+220.66%+113.47%+52.76%DXRDaxor0.00%+2.92%-0.64%+3.89%-20.92%POAIPredictive Oncology0.00%+0.91%+14.01%-23.45%-36.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AN/AN/ABSGMBioSig Technologies1.9293 of 5 stars3.50.00.00.02.60.80.6DXRDaxor4.0338 of 5 stars3.54.00.00.02.43.30.0POAIPredictive Oncology2.558 of 5 stars3.05.00.00.02.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDMDBaird Medical Investment 0.00N/AN/AN/ABSGMBioSig Technologies 3.00Buy$2.5028.87% UpsideDXRDaxor 3.00Buy$25.00222.58% UpsidePOAIPredictive Oncology 2.00Hold$3.00170.27% UpsideCurrent Analyst Ratings BreakdownLatest POAI, BDMD, BSGM, and DXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025BSGMBioSig TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.75 ➝ $2.503/17/2025DXRDaxorAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.75 ➝ $25.00(Data available from 5/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDMDBaird Medical Investment$33.05M1.03N/AN/AN/A∞BSGMBioSig Technologies$40K1,176.22N/AN/A($0.33) per share-5.88DXRDaxor$2.13M17.59N/AN/AN/A∞POAIPredictive Oncology$1.62M6.11N/AN/A$2.04 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDMDBaird Medical InvestmentN/AN/A0.00∞N/AN/AN/AN/AN/ABSGMBioSig Technologies-$29.04MN/A0.00N/AN/A-44,832.50%N/A-776.49%5/19/2025 (Estimated)DXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/APOAIPredictive Oncology-$13.98M-$3.05N/AN/AN/A-1,012.32%-286.30%-122.11%5/13/2025 (Estimated)Latest POAI, BDMD, BSGM, and DXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025N/ABSGMBioSig Technologies-$0.18N/AN/AN/AN/AN/A5/13/2025Q1 2025POAIPredictive Oncology-$0.09N/AN/AN/A$1.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDMDBaird Medical InvestmentN/AN/AN/AN/AN/ABSGMBioSig TechnologiesN/AN/AN/AN/AN/ADXRDaxor$0.030.39%N/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDMDBaird Medical InvestmentN/AN/AN/ABSGMBioSig TechnologiesN/A0.500.50DXRDaxorN/AN/AN/APOAIPredictive OncologyN/A1.201.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDMDBaird Medical Investment19.78%BSGMBioSig Technologies7.16%DXRDaxor1.34%POAIPredictive Oncology9.04%Insider OwnershipCompanyInsider OwnershipBDMDBaird Medical Investment78.90%BSGMBioSig Technologies17.03%DXRDaxor59.00%POAIPredictive Oncology3.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDMDBaird Medical InvestmentN/A6.58 million1.39 millionN/ABSGMBioSig Technologies5024.25 million14.30 millionNo DataDXRDaxor374.84 million1.98 millionNot OptionablePOAIPredictive Oncology308.93 million6.44 millionNot OptionablePOAI, BDMD, BSGM, and DXR HeadlinesRecent News About These CompaniesPredictive Oncology develops new approach to identifying viable abandoned drugsApril 16, 2025 | markets.businessinsider.comRenovaro says Predictive Oncology terminated merger agreementApril 5, 2025 | markets.businessinsider.comPredictive Oncology Stock Price, Quotes and ForecastsApril 2, 2025 | benzinga.comPredictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate UpdateApril 1, 2025 | globenewswire.comPredictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer ResearchMarch 27, 2025 | insidermonkey.comPredictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer ResearchMarch 27, 2025 | msn.comTop 8 AI News Updates Driving Markets TodayMarch 25, 2025 | insidermonkey.comPredictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and OvaryMarch 25, 2025 | globenewswire.comPredictive Oncology completes sale of Skyline Medical assets to DeRoyalMarch 21, 2025 | markets.businessinsider.comPredictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries to Focus on AI-Driven Drug DiscoveryMarch 20, 2025 | quiverquant.comPredictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal IndustriesMarch 20, 2025 | globenewswire.comPredictive Oncology moves to finalize merger agreement with RenovaroMarch 3, 2025 | markets.businessinsider.comRenovaro completes first milestone payment for Predictive Oncology dealMarch 3, 2025 | markets.businessinsider.comPredictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro BiosciencesMarch 3, 2025 | finance.yahoo.comPredictive Oncology Inc. Completes Registered Direct Offering of 363,336 Shares at $1.50 Per ShareFebruary 19, 2025 | quiverquant.comPredictive Oncology Closes Registered Direct OfferingFebruary 19, 2025 | globenewswire.comPredictive Oncology prices 363,336 shares at $1.50 in registered direct offeringFebruary 19, 2025 | markets.businessinsider.comPredictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 19, 2025 | finance.yahoo.comPredictive Oncology (POAI) Struggles AI-Driven Drug Repurposing BreakthroughFebruary 18, 2025 | msn.comPredictive Oncology Inc.: Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug RepurposingFebruary 18, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimePOAI, BDMD, BSGM, and DXR Company DescriptionsBaird Medical Investment NASDAQ:BDMD$5.18 +0.03 (+0.58%) As of 05/9/2025 03:59 PM EasternBaird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.BioSig Technologies NASDAQ:BSGM$1.94 +0.15 (+8.38%) As of 05/9/2025 04:00 PM EasternBioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.Daxor NASDAQ:DXR$7.75 +0.05 (+0.65%) As of 05/9/2025 03:39 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Predictive Oncology NASDAQ:POAI$1.11 +0.04 (+3.74%) As of 05/9/2025 04:00 PM EasternPredictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock Constellation Powers Up With Reinforced AI Data Center Strategy GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
